Elizabeth Buchbinder, MD, assistant professor, Medicine, Harvard Medical School, senior physician, Medical Oncology, Dana-Farber Cancer Institute, discusses the potential implications of the FDA’s decision to grant breakthrough therapy designation to RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) for the treatment of adult patients with advanced melanoma.
Health Professionals
Vulvar and Vaginal Melanoma: A Rare but Important Diagnosis
Cutaneous melanoma is a type of skin cancer typically associated with significant ultraviolet radiation exposure. Melanoma arises from melanocytes, cells found within the lower portion of the epidermis that make the pigment melanin.
Potential Roles for First-Line Targeted Therapy for Advanced Melanoma
Panelists discuss how first-line targeted therapy for advanced melanoma, particularly BRAF and MEK inhibitors, may offer significant benefits in patients with BRAF-mutant tumors, emphasizing rapid response and the potential for combination with immunotherapy to improve long-term outcomes.
UTSW scientists identify cancer-suppressing genetic mutation
DALLAS – Dec. 23, 2024 – UT Southwestern Medical Center researchers identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system.